conditions, and the authors show that the presence of manganese and residual sodium in the catalyst precursor might have been instrumental in the carbide formation and in causing the nanoprism shape to develop.
Some of these findings seem to be serendipitous, but their potential impact cannot be overestimated: they might open up pathways for the development of greatly improved systems for producing valuable chemicals from a variety of carbon sources. The findings also stimulate questions and ideas about the general role of cobalt carbides in the Fischer-Tropsch reaction, and about whether other shapes of cobalt and cobalt carbide nanoparticles are suitable for this process. Other forms of cobalt that have not conventionally been used in this reaction, such as cobalt nitrides, could also now be investigated.
Zhong and colleagues' cobalt-based catalyst might outperform its iron-based counterparts, because it operates at lower temperatures and is therefore potentially deactivated more slowly. However, the preparation of the catalyst is yet to be optimized, as is its formulation -the addition of promoter compounds might increase its performance, for example. Only about 30% of the carbon monoxide used in the reaction is currently converted, and so the operating conditions should also be studied to improve this, while maintaining or increasing the olefin selectivity.
Nonetheless, this is a groundbreaking contribution that further unlocks the immense potential of the Fischer-Tropsch process for producing chemicals. Zhong et al. have thrown open the reaction's treasure chest, and added fresh momentum to research into methods for making olefins from synthesis gas. Perhaps other valuable compounds, such as those that contain oxygen or nitrogen 12, 13 , are also within our grasp. ■ Underactivity of the transcription factor p53 can lead to tumour development. The discovery that the SET protein binds to and inhibits p53 points to a way to unleash the tumour suppressor's activity. See Letter p.118
Michael Claeys is at the Catalysis
n human history, possession of unbridled power has typically ended badly. The same is true in biology, as illustrated by studies of the tumour-suppressor protein p53. Stringent control is required to restrain this transcription factor's potent ability to cause cell death, arrest a cell in stasis or alter the course of metabolism. However, these controls need to be reversible, because p53 must be rapidly activated to protect cells from a wide variety of cellular stresses that promote tumour development 1 . On page 118, Wang et al. 2 reveal a previously unknown mechanism of restraining p53, which involves the formation of a reversible, acidic protein 'shield' that prevents the carboxy-terminal end of p53 from interacting with the cell's transcriptional machinery.
The carboxy-terminal domain (CTD) of p53 is a veritable hub of regulatory signalling. The six lysine residues within this 30-amino-acid region can be modified by several different types of molecule to alter how p53 regulates target genes, the stability of the protein, or its interactions with target DNA 1 . For instance, the addition of acetyl molecules to these lysine residues in response to cellular stressors such as DNA damage activates p53, leading to the transcription of target genes. But despite much research, exactly how this lysine acetylation controls p53's activity has remained unclear.
To drill down into this question, Wang and colleagues began with an unbiased, biochemical approach to identify proteins that interact with the p53 CTD, both when the protein is activated by lysine acetylation and when it lacks acetyl groups and is inactive. Surprisingly, and in contrast to previous studies, the authors found no proteins that bound to the acetylated CTD under their assay conditions, and only one, the tumour-promoting SET protein, that interacted with the unacetylated CTD.
The researchers show that SET acts as a transcriptional co-repressor, inhibiting p53's transcription-factor activity when bound to the CTD (Fig. 1 ). This inhibition relies on reversible electrostatic interactions between positively charged, basic amino acids in the unacetylated p53 CTD and a region of SET comprising long stretches of clustered, highly acidic and negatively charged amino acids.
SET-CTD binding does not disrupt p53's interaction with its target DNA-binding sites, meaning that inactive p53 is poised to activate target genes, which is probably beneficial for a rapid stress response. Instead, SET acts as a shield, preventing the transcriptional co-activator proteins p300 and CBP from interacting with p53 and with nearby DNA and associated histone proteins, and so blocking target-gene activation in the absence of cellular stress.
Wang et al. defined highly acidic domains, such as that described for SET, as stretches of at least 46 amino acids, of which more than 76% of residues are acidic and are found in clusters across the domain. The authors searched the UniProt database 3 for other highly acidic domain proteins, and found only 49 that fitted these criteria, including the p53-interacting proteins DAXX, PELP1 and VPRBP. The group demonstrated that these proteins can bind to the unacetylated, but not the acetylated, p53 CTD. This finding suggests a 2 report that, in the absence of stress and lysine acetylation, a highly acidic, negatively charged domain of the protein SET binds to the positively charged p53 CTD. Although SET-bound p53 can bind DNA, it cannot interact with p300 or CBP, and thus transcription is inhibited.
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Rebalancing the global methane budget
A database of the carbon-isotope 'fingerprints' of methane has been used to constrain the contributions of different sources to the global methane budget. The surprising results have implications for climate prediction. See Letter p.88 broad regulatory role for highly acidic domain proteins in an acetylation switch network, which probably extends beyond p53. However, it is puzzling that these proteins were not identified in Wang and colleagues' original screen. Moreover, it is difficult to reconcile the researchers' shield model of acidic-proteinmediated p53 inhibition with previous characterizations of DAXX (ref. 4 ) and PELP1 (ref. 5) as stress-dependent co-activators of p53.
The physiological importance of inter actions between regulatory proteins and the p53 CTD has been established by engineering mice lacking this domain, which die within two weeks of birth 6, 7 . Wang et al. mutated the six lysine residues in the p53 CTD to glutamines, which mimic the charge and structure of acetylated lysine and so effectively model permanent lysine acetylation. As such, mice harbouring this mutation lack SET binding to the CTD. These animals died within one day of birth, owing to unchecked cell death in the brain and severe neurological defects, underscoring the need for tight control of p53 activity during embryonic development.
By contrast, it has been shown 8 that replacement of lysine with arginine, which mimics a total lack of lysine acetylation -and, presumably, constitutive SET binding -produces no developmental anomalies. To confirm that these effects are attributable to SET, rather than to other highly acidic domain proteins, the authors deleted the mouse gene that encodes SET, which caused embryonic defects and death just before or after birth. Further studies are needed to determine whether this lethality results solely from unchecked p53 activation, or whether other functions of SET are also involved.
SET is a known tumour-promoting protein, and is aberrantly expressed in various cancers of the blood 9 and in solid tumours 10 . Previous studies of SET (for example, ref. 10) have focused mainly on its role as an inhibitor of protein phosphatase 2A (PP2A) -a tumoursuppressor protein that represses multiple signalling pathways that are aberrantly activated in many cancers, including the c-Myc, Wnt and PI3K/Akt pathways. Thus, therapies that inhibit SET may offer opportunities to treat cancer beyond simply unleashing p53. But such treatments must also take into consideration the complex consequences of altering SET activity.
In support of the therapeutic potential of targeting SET, Wang et al. showed that inhibition of SET production in mice led to regression of tumours with normal p53 levels, but not of tumours lacking the protein. However, concerns remain. For instance, tumours frequently harbour single-nucleotide mutations that alter the amino-acid sequence of p53 and so lead to production of a mutant protein. Disrupting SET-p53 interactions in cells carrying such mutations might lead to activation of a mutant protein that has deleterious tumour-promoting activities.
Profiling of the genomic regions with which SET is associated is now needed to determine: the breadth of p53-regulated genes affected by SET; whether SET's role is restricted to specific developmental stages or tissues; and whether p53 mutations that are implicated in cancers alter SET control and response. Moreover, studies that used SET inhibitors to increase PP2A activity in cancer 10 should be reinterpreted in light of the newly revealed role of SET as a protein shield. Combining SET inhibitors with drugs that inhibit lysine deacetylation 
G R A N T A L L E N
G lobally averaged concentrations of atmospheric methane, a potent greenhouse gas, continue to rise. Explaining this trend by accurately accounting for sources and sinks of atmospheric methane gas remains a key challenge in climate science. On page 88, Schwietzke et al. 1 account for methane sources on the basis of a new carbon-isotope database. Their findings suggest that methane emissions associated with fossil-fuel use and production might be 20-60% higher than in current global inventories.
Methane is the second-largest contributor to climate radiative forcing -the change in energy trapped in the atmosphere as a result of greenhouse-gas emissions -and has a globalwarming potential 28-34 times that of carbon dioxide (by equivalent mass) over a 100-year time frame 2 . So although average atmospheric methane concentrations are about 200-fold smaller than those of CO 2 , understanding the causes of increases in global methane concentration is just as important as understanding those for increasing CO 2 levels, to aid climate prediction and inform emissions-reduction policy.
Atmospheric methane concentrations have been rising since the Industrial Revolution. A hiatus in this rise occurred between 1999 and 2006, although there is little consensus on the possible reasons for this -which vary from a reduction in coal mining and gas-industry emissions, especially in the countries of the former Soviet Union (see refs 3-5, for example), to the offsetting of increased anthropogenic emissions by decreasing wetland emissions 4, 6 . Other studies have attributed the hiatus, at least in part, to changes in chemical species (reactive sinks) in the environment that react with methane 7, 8 , to reduced emissions from rice paddies 9 or simply to a plateauing of emissions from microbial and fossil-fuel sources 10 . The range of competing explanations exemplifies the complexity and uncertainty of balancing the global methane budget. But one thing is clear: methane levels have since vigorously resumed their upward trend 11 , attracting strong and renewed scientific interest.
The scale of efforts to understand the most recent increases reflects the fact that researchers cannot easily explain the observed trend by comparing the rate of emissions with the rate at which methane is expected to be lost from the atmosphere through chemical reactions that occur in the environment. But the race to close the current global methane budget is just a sprint. A marathon effort is also required to take into account predicted changes in future human activity and the potential consequences
